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1. INTRODUCTION
Biobanks – collections of human biological specimens stored for future research use – are
crucial for biomedical advancement. Our prior research revealed that biobanks acquire
specimens in a variety of ways [1]. One of the most common is to obtain residual or
“leftover” specimens originally collected for clinical care from hospitals, clinical
laboratories and pathology departments. However, there is a longstanding concern about the
appropriateness of using stored specimens in ways not originally intended when they were
collected [2–5].
In 1999, in response to remarkable developments in biomedical technologies applied to
research with human specimens, the National Bioethics Advisory Commission issued a
report on ethical and policy issues involving human biological materials [6]. It addressed the
question of re-purposing clinical specimens for research use, and made three
recommendations to assist interpretation of the Common Rule – the existing federal
regulations governing human subjects protections. First, the Commission recommended that
research conducted with unidentified clinical samples (that is, when identifying information
is not collected or retained) not be deemed human subjects research and therefore not be
regulated by the Common Rule. Second, the Commission recommended that research
conducted with unlinked (or “anonymized”) samples be defined as research on human
subjects and regulated by the Common Rule, but eligible for exemption from Institutional
Review Board (IRB) review. Finally, it recommended that research conducted with coded or
identified samples be treated as research on human subjects and regulated by the Common
Rule [6]. In 2004 (and later updated in 2008), these recommendations were reflected in
guidance on secondary use of biospecimens issued by the federal Office for Human
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Research Protections [7]. This guidance has important implications for whether and when
consent must be obtained from contributors for the use of their samples.
Advances in genomics have continued to frame ethical considerations regarding informed
consent and protection of contributor identities. Discoveries published in 2008 and later
challenged the prevailing assumption that “de-identification” of samples containing genomic
DNA is technically achievable, and therefore also challenged the adequacy of privacy
protections that depend upon de-identification [8,9]. In July 2011, the federal government
published an Advance Notice of Proposed Rule Making (ANPRM), entitled “Human
Subjects Research Protections: Enhancing Protections for Research Subjects and Reducing
Burden, Delay, and Ambiguity for Investigators,” in the Federal Register [10,11]. Several of
the proposed changes are highly relevant to the matters discussed here. One mandates
written informed consent for any use of biospecimens, regardless of their identifiability and
the original purpose for which they were obtained (i.e., clinical or research). Another
proposes that consent should be obtained via a standardized form that would accommodate
all future uses in a broad, open-ended manner. Response from the public was solicited, and
over one thousand comments were submitted and posted. Many argued that mandated
consent was “wholly unworkable,” “…a logistical quagmire that will inhibit research,” and
that “The requirement for written permission to use de-identified specimens for research
would profoundly impede clinical research for biomarkers and basic science studies.” One
lamented, “Loss of ability to use certain types of archived tissues without obtaining consent
may be the death knell of live-saving translational research” (emphasis added).1
While controversy over how to adequately protect contributor identifiability continues, the
environments in which such collections exist are also quite complex. Biospecimens acquired
from clinical sources may be collected by pathology departments and clinical laboratories in
academic medical centers, by biobanks associated with cancer centers or repositories
focused on other types of patient populations, or by researchers with specific clinical
research aims. Specimens may be stored with no explicit research intent, or acquired
specifically for research purposes; collections may include specimens from a single source
or multiple ones [1]. Biobanks’ most salient feature is to store specimens for research
purposes; they are challenged to ensure that research use of specimens from clinical sources
adheres to federal guidelines. At the same time, clinical laboratories, whose most salient
feature is to provide clinical diagnostic services, are increasingly challenged to consider how
their clinical collections may be used by biobanks, and the extent to which consent for
clinical uses anticipates such applications [12].
Little is known about biobanks that store specimens from clinical sources. There are no
national data on these banks, nor even a unified definition. A number of authors have
acknowledged the diversity of biobanks in the U.S. [13–16], which our 2012 national survey
of U.S. biobanks demonstrated empirically [1,17,18]. In this paper, we address the particular
ethical issues described above, focusing on biobanks in the 2012 survey that store
collections from clinical sources—either solely or in conjunction with specimens from other
sources.
2. METHODS
In 2012 we conducted a survey of U.S. biobanks--which we define as “organizations that
acquire and store human specimens and associated data for future research use.” We
identified 636 eligible biobanks and 456 (72%) responded to our survey. Details on biobank
1These quotes come from ANPRM comments that two of the authors analyzed for another project examining commenters’ responses
to the proposal to mandate written informed consent for the collection of all human specimens.
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identification and survey data collection may be found elsewhere [1]. In this paper we
present simple response frequencies, with percentages where appropriate. Where
percentages do not add to 100, it is due to rounding. Analyses were conducted in SAS
version 9.2 (SAS Institute Inc., Cary, NC, USA).
3. RESULTS
3.1 SPECIMEN COLLECTIONS
In identifying biobanks for our study, we tried to eliminate organizations that serve solely as
storage facilities for individual researchers—ones in which a researcher deposits specimens
until they are needed, with no possibility that the specimens could be shared with others. We
did not place any requirement on how the biobank acquires its specimens in order to be
eligible for our study. Within the survey, we asked whether any of the specimens in the
biobank’s collection come from each of the following sources:
1. Hospitals, clinical laboratories, or pathology departments providing residual
specimens from clinical care
2. Public health departments or programs providing residual specimens
3. Individuals providing specimens directly to the biobank
4. Any other source(s).
For this paper, we focus only on the 261 biobank managers who said “yes” to the first
source. As shown in Table 1, forty-three respondents (16%) reported that their biobank
acquires specimens only from hospitals, clinical laboratories, or pathology departments. One
hundred thirty-eight banks (53%) acquire specimens from clinical settings and from
individuals providing specimens directly. Thirty-nine (15%) acquire them from clinical
settings, from individuals directly, and from “other” sources; twenty-seven (10%) acquire
specimens from clinical and other sources. Only 7 biobanks (3%) acquire specimens from
all four sources, and the remaining 7 biobanks (3%) acquire from clinical and public health
settings, with or without collecting from individuals as well. Since we did not ask the
respondent to indicate the number of specimens acquired from clinical settings relative to
others in their collection, we do not know, for the 218 biobanks with mixed sources, whether
the clinical specimens form only a small portion of their collection, nearly the entirety of it,
or something in between.
Table 2 shows the number and percentage of biobanks storing various types of biological
specimens. Solid tissue and serum/plasma are the most common. Twenty-four biobanks
reported “other biological specimens,” meaning they store something not listed on our
survey. Nineteen of these wrote in a description of the “other” specimens, which are detailed
in Table 3. Most biobanks (88%) store more than one type of specimen. As shown in Table
4, biobanks reported as many as 10 different types of specimens in their collections. The size
of the specimen collection (number of specimens currently in storage) ranged from only 20
specimens to 54 million. Table 5 provides more detail on the number of specimens in
storage. The range most frequently reported by the surveyed biobanks (19%) was that of
10,000–49,999 specimens. Due to a few very large banks, the mean number of specimens is
610,245 but the median is 7650.
Also of interest in describing a biobank’s collection is whether pediatric and/or post mortem
specimens are included. In our survey, six biobanks (2%) house exclusively pediatric
specimens, and an additional 44% include some pediatric specimens. Seven percent of
biobanks report collections composed entirely of specimens that were collected post
mortem; an additional 37% contain some post mortem specimens. Thus we found
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tremendous variation in the size and nature of specimen collections among these biobanks
housing clinical specimens
3.2 ORGANIZATIONAL FEATURES AND PRACTICES
Among the 261 biobanks with collections that include clinical specimens, 15 (6%) are for-
profit organizations; the remainder are not. The vast majority (89%) are part of some larger
organization – most often an academic institution or a hospital/health care organization.
Since our survey was primarily designed to study the ethical, legal, and social issues
surrounding biobanking rather than technical processes, we did not gather detailed
information about the biobank’s day-to-day operations. We did, however, ask a few
questions which provide a snapshot of the general operations of these biobanks and the
policies and practices in place. We asked for an approximation of the number of specimens
the biobank received for processing in the past year. Responses ranged from zero to 5
million, with a mean of 42,486 and median of 500. Ninety-three percent of biobanks have
standard operating procedures (SOPs) for processing their specimens. Eighty-four percent
have a Laboratory Information Management System (LIMS), which we defined as “a
computer-based inventory system that tracks the location and status of every specimen in the
biobank.” Seventy-five percent have standardized material transfer agreements (MTAs), and
80 percent have application forms through which researchers request specimens. Ninety-one
percent of biobanks require studies that use their specimens to be approved by an
Institutional Review Board (IRB). Only 33%, however, have a formal business plan, and
even fewer (27%) have a written plan for what will happen to the specimens should the
biobank be terminated for any reason.2
3.3 INFORMED CONSENT
Our survey included several items about whether and how informed consent is obtained for
specimens stored by the biobank. Because procedures may not be the same for all specimens
contained in a biobank’s collection, we asked about typical consent procedures. We did not
ask whether the biobank itself obtains consent from contributors, in recognition that a
clinical staff member or other personnel might be the one to interact with the potential
contributor rather than the biobank’s own staff.
Figure 1 depicts our questions about informed consent, with corresponding response
frequencies. Almost all biobanks (96%) indicated that specimen contributors are typically
informed that their specimens will be stored. Among those, an opt-in method (which we
defined as “where contributors are asked for permission to store their specimens”) is
typically used (79%), with 13% using opt-out and 9% reporting use of “both” or other
methods unique to their situation. Among the biobanks using opt-in consent, most (79%) use
broad language which allows use for any future research purposes. Twelve percent use more
limited language, 7% report use of both types, and 3% wrote responses to the “other,
specify” request, which were later renamed “tiered” because the contributor is typically
given a choice about whether their specimens will be used only for a designated purpose or
they may be used for other research aims that arise in the future.
3.4 RETURN OF RESULTS
For those biobanks that report having access to identifying information for any of its
specimen contributors, we asked whether they return results to the individuals whose
specimens are used for research studies. Only 15% of biobanks said “yes” when asked if
2An additional nineteen percent of biobank respondents were “not sure” whether a written plan exists.
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they “ever” return individual results to contributors. Thirty-four percent said they may (ever)
return aggregate results.
Regardless of whether they report ever returning results, we asked biobanks whether they
have a policy about returning individual results to contributors, and if so, what the policy
states and whether it speaks to the issue of incidental findings, which we defined as
“findings beyond the aims of the research.” Figure 2 provides a graphic representation of the
question sequence. Sixty-three percent of biobanks have policies about return of individual
results to specimen contributors. In most cases (64%), the policy states that such results will
never be returned. In 33%, results will be returned under certain conditions, and in only 3%
will individual results always be returned.
In 48% of biobanks with policies about return of results, the policy addresses the question of
incidental findings. Among policies of these 67 biobanks, 51% state that incidental findings
will never be returned, 46% specify it under certain conditions, and 3% state that incidental
findings will always be returned.
3.5 SPECIMEN AND TECHNOLOGY OWNERSHIP
Who owns the specimens in a biobank? This question has garnered interest in the scientific
community. We asked our survey respondents whether their biobank has a policy about
specimen ownership. (See Figure 3.) For those who said yes, we asked who owns the
specimens according to the policy; for those who said no, we asked the respondent’s own
opinion about ownership. We offered five response options and an “other, specify” category.
3 Respondents could choose as many as they wished. Among those with written policies, the
most commonly chosen response (52%) was the larger organization that the biobank is a
part of. Forty-three percent identified the biobank itself as an owner. Twenty-six percent
identified the researcher who collected or deposited the specimens as an owner, and 8%
chose the specimen contributor as an owner. For respondents who were asked their own
opinion about ownership, the percentages vary slightly as shown in Figure 2. The
differences could reflect discrepancy between policy and opinion, or could reflect the
difference in organizations which have policies (potentially more formal ones) compared to
those that do not.
We asked respondents a parallel question sequence about ownership of the rights to
technologies developed from research using their biobank’s specimens (See Figure 4).
Among those with written policies, again, the most common response was the larger
organization that the biobank is a part of (69%) and next was the researcher or entity that
developed the technology (44%). The responses follow the same order but with slight
differences in percentages among respondents who were asked their own views on
technology ownership.
3.6 USERS AND PERCEPTION OF UNDERUTILIZATION
What level of specimen use is achieved by biobanks? We asked respondents how many
requests for specimens they receive on average per year. The distribution of responses is
shown in Table 6. The most frequent response (26%) was “6 to 15 per year,” followed by “1
to 5 per year” (22%) and “16 to 50 per year” (20%). Thus, two thirds of these biobanks
receive between 1 and 50 requests per year for their specimens. Most (81%) report that
researchers typically obtain specimens and data together; 17% report that requests are
typically for specimens only, and only 2% of biobanks indicate that requests are typically for
3The response options for “larger organization biobank is part of” and “Network biobank belongs to” were only presented to biobanks
which had previously indicated they were part of these.
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data only. Asked whether they typically approve (fulfill) all, some, or none of the requests
they receive, 41% of biobanks report approving all requests, 58% approve some, and 2
banks (1%) approve none of the requests they receive. Forty-two percent of biobanks
typically charge researchers for use of specimens (excluding shipping and handling); the
remainder do not.
Who are the users of these biobanks containing clinical specimens? Thirty-six percent of the
biobanks report that all requests they approve come from within their own organization or a
larger organization of which they are a part. We asked the remaining 157 biobanks to
identify the types of organizations from which approved requests came. As shown in Table
7, virtually all (96%) biobanks had received one or more requests from academic
researchers. Fifty-four percent had received request(s) from a researcher affiliated with a
research institute; 48% had received requests from researchers in the federal government.
Researchers in hospital/health care organizations or the pharmaceutical industry were also
common (41% and 40%, respectively).
Based on qualitative work conducted prior to the survey [18], we posed the following
question to biobank survey respondents:
We have heard from some biobanks that they are concerned that their specimen
collection is being underutilized. How much of a concern is this for (biobank
name)?
Fourteen percent of respondents felt that it was a major concern. The remainder were
equally spread across categories of “a moderate concern,” “a minor concern,” or “not at all a
concern.” However, we do not know whether expressing little or no concern means the
biobank receives the number of requests it deems appropriate, or that utilization rate is
simply not of interest.
3.7 DISPOSITION OF REMAINING SPECIMENS
Biobanks differ in their policies regarding the disposition of remaining samples when the
researcher has finished his or her research. Thirty-three percent of these biobanks require
researchers to return remaining specimens. Eighteen percent require researchers to destroy
the remaining samples, while the rest of the biobanks place no restrictions.
4. DISCUSSION
We present data from our 2012 U.S. biobank survey for the subset of biobanks that report
storing specimens from clinical sources. Only 16% (N=43) indicated that this was their only
source of specimens; over half reported that specimens were obtained from clinical sources
and directly from individual specimen contributors. Other combinations were also reported,
demonstrating the heterogeneity in composition of these biobank collections. Similar
heterogeneity was documented regarding number and type of specimens stored, and number
of requests for specimens per year. Only a few (6%) are for-profit, and nearly 90% are part
of larger organizations, mainly academic medical centers. Most report standardized systems
for managing acquisition, storage, and release to researchers. Lastly, we document
considerable heterogeneity in policies and practices regarding informed consent, return of
research results, ownership of specimens and technology developed, utilization and
disposition of remaining specimens.
Although unified federal regulations for human subjects protections, codified under the
Common Rule, apply to biobank activities, acquisition of specimens and their release for
research purposes is overseen by multiple institutional review boards (IRBs) who set
policies in the context of both federal regulations and local needs. Variation in these policies
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is matched by dramatic differences in biobank goals, daily governance, and the diversity in
composition of their specimen collections. Responding to this variation presents significant
challenges for those who manage the collections and those who use biological samples for
research.
Issues of consent are particularly challenging for those who maintain banked specimens.
Commensurate with the significant heterogeneity observed in other aspects of biobanking,
the type of consent by specimen contributors for research use varies considerably, although
the majority of biobanks report using opt-in [1]. When a biobank is created to house
research collections, contributors are often asked for their permission to store at the time of
collection. In these cases, consent to storage for unspecified future research purposes is
facilitated by broad or global permissions, and this appears to be the predominant type of
consent overall [1], and for the sub-set of biobanks featured here. More controversy has
surrounded opt-out approaches, defined as notification that specimens will be stored unless
contributors refuse [19]. The controversy focuses on whether individuals truly understand
that their specimens will be used for research, and reflects a longstanding concern about the
appropriateness of using stored specimens in ways not originally intended when they were
collected. These are more than just theoretical questions for those who direct biobanks as
they must carefully balance facilitating research and protecting human subjects.
Another increasingly thorny issue for those who direct and use specimen repositories is
whether they are responsible to return results to subjects when generated in the course of
research studies [20]. A number of authors have pointed to the potential for this
development to blur the boundary between clinical care and research, with uncertain
implications for biobank policies and for clinical labs that contract with them. Such
uncertain responsibilities are triggered when, as one author notes, “the diagnosis on a
specimen during the course of review at a biobank differs from the original clinical
diagnosis” [21]. In addition, while most such results transpire in research laboratories, CLIA
(Clinical Laboratory Improvement Act) and other regulatory agencies mandate that results
used for patient care be obtained in a certified laboratory by appropriate staff; some
institutions have additional policies regarding this and restrict testing in research
laboratories. Our survey results clearly document that existing policies at the level of
individual biobanks are highly heterogeneous with regard to return of results. Such local
variation may not contradict recommended principles and processes, yet broad community
consensus is still desirable. Some recommendations have been put forward [13,22], but no
firm, over-arching policies have yet been articulated. For the time-being, then, individual
biobanks and their IRBs must formulate and document their own policies. Certainly those
biobanks that do not retain identifying information about specimen contributors are not in
the position to return results from research studies. Some biobanks may retain contact
information, but choose not to return any results to subjects, while others develop policies
for return of certain findings that when rising to the level of a clear, preventable harm,
should be returned [13,23]. Whatever specific policies are adopted by an individual biobank,
if that policy is to return research results to subjects, then the issue of CLIA confirmation
must be addressed. The perceived advantages of research results to subjects must be
balanced with practical realities such as a need for clinical personnel to evaluate and deliver
such results to subjects – who then become patients – accentuating the blurring of research
and clinical activities.
As we document, the world of this sub-set of 261 biobanks is highly variable in the types
and numbers of specimens maintained and the policies that govern them. This uncertain and
heterogeneous landscape demands careful consideration and planning by biobank managers
to maintain high quality practices in acquisition, storage, and release of specimens all the
while striving to protect the rights of subjects. Vaught and Lockhart, in a recent article,
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outline the importance of best practices in biobanking to improve research and clinical
outcomes. While advocating for the application of NCI (National Cancer Institute) and
ISBER (International Society for Biological and Environmental Repositories) standards for
technical aspects, they also note, “In contrast to the more straightforward technical and
management issues, ethical and regulatory practices often involve issues that are more
controversial and difficult to standardize.” [24] As we argue above, ethical and regulatory
practices are developed within particular contexts, and are appropriately diverse. However,
in order to evaluate this diversity, it is essential to understand practices currently being
employed by biobanks that store clinical specimens.
Acknowledgments
We wish to thank the people who kindly participated in our survey, and members of our biobank research team at
UNC, including Ian Conlon, Arlene Davis, Bryan Weiner, and Cathy Zimmer. Kriste Kuczynski created the figures
and Warren Whipple assembled the references. Funding for this research was provided by several grants:
1R01HG005227-01A1 (G. Henderson, principal investigator, ‘From Specimen to Biobank: Using An
Organizational Perspective to Study ELSI Issues’) from the National Human Genome Research Institute;
5UL1RR025747-04S1, a supplement to the UNC CTSA U54RR024382-01A1 (Runge, M., principal investigator,
‘Enhancing Biobank Capacities Across CTSAs’); and the UNC Center for Genomics and Society, P50 HG004488,
from the National Human Genome Research Institute. The content of this article does not necessarily reflect the
views or policies of the funding agencies.
References
1. Henderson GE, Cadigan RJ, Edwards TP, Conlon I, Nelson AG, Evans JP, et al. Characterizing
biobank organizations in the U.S.: results from a national survey. Genome Med. 2013; 5:3.
[PubMed: 23351549]
2. Clayton E, Steinberg KK, Khoury MJ, Thomson E, Andrews L, Kahn MJE, et al. Informed consent
for genetic research on stored tissue samples. J Am Med Assoc. 1995; 274:1786–1792.
3. American College of Medical Genetics, Storage of Genetics Materials Committee. ACMG
statement. Statement on storage and use of genetic materials. American College of Medical
Genetics Storage of Genetics Materials Committee. Am J Hum Genet. 1995; 57:1499–1500.
[PubMed: 8533780]
4. Merz JF. Is Genetics Research “Minimal Risk”? IRB. 1996; 18:7–8. [PubMed: 11654745]
5. Merz JF, Sankar P, Yoo SS. Hospital Consent for Disclosure of Medical Records. J Law Med
Ethics. 1998; 26:241–248. [PubMed: 11066882]
6. National Bioethics Advisory Commission. Research involving human biological materials: ethical
issues and policy guidance. Rockv. MD: US Gov. Print. Off; 1999.
7. Office for Human Research Protections (OHRP). [Accessed Nov. 24, 2013] Guidance on Research
Involving Coded Private Information or Biological Specimens. 2004. Available at http://
archive.hhs.gov/ohrp/humansubjects/guidance/cdebiol04.htm
8. Homer N, Szelinger S, Redman M, Duggan D, Tembe W, Muehling J, et al. Resolving Individuals
Contributing Trace Amounts of DNA to Highly Complex Mixtures Using High-Density SNP
Genotyping Microarrays. PLoS Genet. 2008; 4:e1000167. [PubMed: 18769715]
9. Gymrek M, McGuire AL, Golan D, Halperin E, Erlich Y. Identifying personal genomes by surname
inference. Science. 2013; 339:321–324. [PubMed: 23329047]
10. Health and Human Services Department. Human Subjects Research Protections: Enhancing
Protections for Research Subjects and Reducing Burden, Delay, and Ambiguity for Investigators.
Fed Regist. 2011
11. Emanuel EJ, Menikoff J. Reforming the Regulations Governing Research with Human Subjects. N
Engl J Med. 2011; 365:1145–1150. [PubMed: 21787202]
12. McDonald SA, Watson MA, Rossi J, Becker CM, Jaques DP, Pfeifer JD. A New Paradigm for
Biospecimen Banking in the Personalized Medicine Era. Am J Clin Pathol. 2011; 136:679–684.
[PubMed: 22031304]
Edwards et al. Page 8













13. Wolf SM, Crock BN, Van Ness B, Lawrenz F, Kahn JP, Beskow LM, et al. Managing incidental
findings and research results in genomic research involving biobanks and archived data sets. Genet
Med. 2012; 14:361–384. [PubMed: 22436882]
14. Beskow LM, Burke W. Offering individual genetic research results: Context matters. Sci Transl
Med. 2010; 2:38cm20.
15. Bledsoe MJ, Grizzle WE, Clark BJ, Zeps N. Practical implementation issues and challenges for
biobanks in the return of individual research results. Genet Med. 2012; 14:478–483. [PubMed:
22323073]
16. Gibbons SMC. Regulating Biobanks: A Twelve-Point Typological Tool. Med Law Rev. 2009;
17:313–346. [PubMed: 19671622]
17. Boyer GJ, Whipple W, Cadigan RJ, Henderson GE. Biobanks in the United States: How to identify
an undefined and rapidly evolving population. Biopreservation Biobanking. 2012; 10:511–517.
18. Cadigan RJ, Lassiter D, Haldeman K, Conlon I, Reavely E, Henderson GE. Neglected ethical
issues in biobank management: Results from a U.S. study. Life Sci Soc Policy. 2013; 9:1–13.
19. Pulley J, Clayton E, Bernard GR, Roden DM, Masys DR. Principles of human subjects protections
applied in an opt-out, de-identified biobank. Clin Transl Sci. 2010; 3:42–48. [PubMed: 20443953]
20. Wolf SM. The past, present, and future of the debate over return of research results and incidental
findings. Genet Med. 2012; 14:355–357. [PubMed: 22481182]
21. Lockhart NC, Yassin R, Weil CJ, Compton CC. Intersection of biobanking and clinical care:
should discrepant diagnoses and pathological findings be returned to research participants? Genet
Med. 2012; 14:417–423. [PubMed: 22344228]
22. NCI Office of Biorepositories and Biospecimen Research. NCI best practices for biospecimen
resources. 2011.
23. Evans JP, Rothschild BB. Return of results: not that complicated? Genet Med. 2012; 14:358–360.
[PubMed: 22481183]
24. Vaught J, Lockhart NC. The evolution of biobanking best practices. Clin Chim Acta. 2012;
413:1569–1575. [PubMed: 22579478]
Edwards et al. Page 9













• We present national survey data from 261 biobanks that store specimens from
clinical sources.
• Most are part of larger academic organizations, and report standardized systems
for managing acquisition, storage, and release to researchers.
• We found heterogeneity in the sources, number and type of specimens, and
number of requests/year; and heterogeneity in policies and practices regarding
informed consent, return of research results, ownership of specimens and
technology developed, utilization, and disposition of remaining specimens.
• Responding to this variation presents significant challenges for those who
manage collections.
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Survey questions and response frequencies on contributor consent for specimen storage
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Survey questions and response frequencies on return of individual results
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Survey questions and response frequencies on specimen ownership
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Survey questions and response frequencies on rights to new technologies
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Table 1
Sources for acquisition of specimens
Source(s) n %
Clinical and direct contributions 138 53%
Clinical only 43 16%
Clinical, direct contributions, and “other” 39 15%
Clinical and “other” 27 10%
Clinical, public health dept/program, direct contributions, and “other” 7 3%
Clinical and public health dept/program 5 2%
Clinical, public health dept/program, and “other” 2 1%
Total 261 100%
Clinical: Hospitals, clinical laboratories, or pathology departments providing residual specimens from clinical care
Public health dept/program: Public health departments or programs providing residual specimens
Direct contributions: Individuals providing specimens directly to the biobank
“Other”: Any other source(s)
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Table 2
Types of specimens in storage (check all that apply)
Percentage of biobanks storing specimens of this type n %
Solid tissue specimens, including paraffin embedded, frozen, or other 231 86%
Serum or plasma 203 79%
Whole blood 147 56%
Peripheral blood cells or bone marrow 138 53%
Cell lines 95 36%
Saliva or buccal cells 85 33%
Urine or stool 83 32%
Cerebral spinal fluid 59 23%
Cord blood or cord blood derivatives 30 11%
Pathological body fluids 27 10%
Other biological specimens 24 9%
Hair/toenails 6 2%
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Table 3
Other types of biological specimens (Each type below was reported by only one biobank)
Amniotic fluid
Bronchoalveolar lavage
Monoclonal antibodies, biological research reagents
Muscle, hair, pituitary
Over 200 human, animal and environmental material types
Seminal plasma
Animal and human specimens of all kinds
Bacterial plasmids
Body fluids, tissue scrapings, aspirates, swabs, cultures, extracted DNA or RNA
Bone
Breast milk
Breast milk, meconium, dust, placenta, buffy coats, dried blood spot cards
Cell pellets




Seminal vesicle, prostatic fluid, fresh tissue
Sperm, oocytes, embryos & semen
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Table 4
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Table 5
Number of specimens in storage
n %
Less than 500 30 12%
500–999 19 8%
1000 – 1999 23 9%
2000–4999 34 14%
5000–9999 24 10%
10,000 – 49,999 48 19%
50,000 – 99,999 24 10%
100,000 – 499,999 30 12%





Range: 20 – 54,000,000
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Table 6
Number of Requests for Specimens and/or Data Received Per Year
n %
0 per year 6 2%
1 to 5 per year 56 22%
6 to 15 per year 65 26%
16 to 50 per year 49 20%
51 to 100 per year 32 13%
101 to 500 per year 28 11%
501 to 1000 per year 6 2%
More than 1000 per year 9 4%
Total 251 100%
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Table 7
In the past year, have any of the approved requests come from researchers who work for…
n %
Academic institutions (including medical centers and academic research centers) 151 96%
Research institutes (including contract research organizations) 85 54%
The federal government (including NIH and CDC) 76 48%
Hospitals or health care organizations 65 41%
Pharmaceutical companies 63 40%
Disease or health advocacy organizations 18 11%
State government (including public health departments) 7 4%
Insurance companies 1 1%
Based on 157 biobanks who received this survey question.
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